Sharp·PS®GOLD Gains Australian Patent

MORRISTOWN, N.J.A patent for Enzymotecs Sharp·PS®GOLD was accepted in Australia regarding methods for improving cognitive and behavioral parameters by administration of phosphatidylserine (PS) containing the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). The patent "Glycerophospholipids containing omega-3 and omega-6 fatty acid" (Pat. No. 2004282006) covers Sharp·PS®GOLD, which is designed to mimic brain PS.

According to the company, recent clinical studies demonstrated Sharp·PS®GOLDs capacity to significantly increase DHA levels in the brain and subsequently improve cognitive performance due to the combined action of PS and DHA. Recently the Sharp-PS® -brand line was extended by the addition of Krill-PS into Enzymotec's product portfolio

"The Australian market is an important market that holds a big potential for Enzymotec's products due to its dynamic nature and proximity to South East Asia" said Gil Kirtovsky, business unit manager, Enzymotec. "There are numerous pending patents covering process, efficacy, health benefits and composition of our products around the world."

Enzymotec is a biotech company and a global developer, producer and supplier of lipid-based products and solutions. Enzymotec develops, manufactures and markets innovative bio-active ingredients and finished products based on proprietary technologies. Enzymotec's products support general health, from cardiovascular to cognitive functions, and deliver solutions in three business segments: orthomolecular medicinepractice of preventing and treating diseases by providing the body with optimal amounts of substances that are natural to the body, infant nutritionproviding lipid compositions that mimic the fat in human milk for the wellbeing of infants, and bioactive ingredientsproviding ingredients for the pharma , dietary supplements and functional foods markets.